{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:29Z","timestamp":1793109749134,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pembrolizumab is a monoclonal antibody approved for adult patients with advanced non\u2013small-cell lung cancer (NSCLC). Although immune related adverse events are considered to be well tolerated, complications may occur and discontinuation of the treatment could be required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 62-year old patient diagnosed with advanced non-small cell lung cancer experienced a decline in the renal function after seven cycles with pembrolizumab. Management &amp; outcome: After ruling out other common causes of interstitial nephritis, pembrolizumab was attributed as a cause of interstitial nephritis. At first, toxicity was managed with corticosteroids and closely monitoring the patient, but finally pembrolizumab had to be discontinued due to the kidney function did not recover.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Renal and urinary disorders were reported in &lt;3% of patients treated with pembrolizumab, being interstitial nephritis the most reported toxicity. The kidney damage can be a complication to consider in patients receiving pembrolizumab. Early identification of an increase in serum creatinine levels may help with prevention by establishing an effective treatment, although it may not mean a total recovery of kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220961553","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T04:52:54Z","timestamp":1602478374000},"page":"1046-1051","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Interstitial nephritis with pembrolizumab: A case report and review"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-0481","authenticated-orcid":false,"given":"A","family":"Pel\u00e1ez Bejarano","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Farmacia, Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Montero P\u00e9rez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Farmacia, Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Inoriza Rueda","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Oncolog\u00eda M\u00e9dica, Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MT","family":"Garrido Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Farmacia, Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"bibr1-1078155220961553","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.12.23"},{"key":"bibr2-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy100"},{"key":"bibr3-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"bibr4-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"bibr5-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr6-1078155220961553","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"Izzedine H","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"bibr7-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0764"},{"key":"bibr8-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"bibr9-1078155220961553","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55050176"},{"key":"bibr10-1078155220961553","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3928-19"},{"key":"bibr11-1078155220961553","doi-asserted-by":"crossref","unstructured":"Couey MA, Bell R, Patel A et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.\n                      J Immunotherapy Cancer\n                      2019; 7: 165.","DOI":"10.1186\/s40425-019-0645-6"},{"key":"bibr12-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"bibr13-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"bibr14-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2718-y"},{"key":"bibr15-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1159\/000491631"},{"key":"bibr16-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.06.001"},{"key":"bibr17-1078155220961553","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.04.016"},{"key":"bibr18-1078155220961553","doi-asserted-by":"crossref","unstructured":"Belliere J, Meyer N, Mazieres J et al. Acute interstitial nephritis related to immune checkpoint inhibitors.\n                      Br J Cancer\n                      2016; 115(12): 1457\u20131461.","DOI":"10.1038\/bjc.2016.358"},{"key":"bibr19-1078155220961553","doi-asserted-by":"crossref","unstructured":"Glutsch V , Gr\u00e4n F,  Weber J,  Gesierich A,  Goebeler M,  Schilling B. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.\n                      J Immunother Cancer\n                      2019; 7: 181.","DOI":"10.1186\/s40425-019-0655-4"},{"key":"bibr20-1078155220961553","doi-asserted-by":"crossref","unstructured":"Escandon J, Peacock S, Trabolsi A, Thomas DB, Layka A, Lutzky J. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.\n                      J Immunother Cancer\n                      2017; 5: 3.","DOI":"10.1186\/s40425-016-0205-2"},{"key":"bibr21-1078155220961553","doi-asserted-by":"crossref","unstructured":"Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.\n                      J Immunother Cancer\n                      2019; 7(1): 2.","DOI":"10.1186\/s40425-018-0478-8"},{"key":"bibr22-1078155220961553","doi-asserted-by":"crossref","unstructured":"Shah N, Jacob J, Househ Z, Shiner E, Baird L, Soudy H. Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab.\n                      J Immunother Cancer\n                      2019; 7: 247.","DOI":"10.1186\/s40425-019-0727-5"},{"key":"bibr23-1078155220961553","doi-asserted-by":"crossref","unstructured":"Perazella M,  Sprangers B. AKI in Patients Receiving Immune Checkpoint Inhibitors.\n                      Clin J Am Soc Nephrol\n                      2019; 14(7): 1077\u20131079.","DOI":"10.2215\/CJN.02340219"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220961553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220961553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220961553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:51Z","timestamp":1777688631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220961553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1078155220961553"],"URL":"https:\/\/doi.org\/10.1177\/1078155220961553","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}